Edgar Filing: Kindred Biosciences, Inc. - Form 4

Kindred Bioscien Form 4	nces, Inc.										
January 12, 2016											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB APPROVAL		
	UNITED	STATES		RITIES A Ashington			COMMISSIO	N OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations	16(a) of th	RITIES ne Securi	Estimated burden hou response	urs per							
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).											
(Print or Type Respo	nses)										
1. Name and Address of Reporting Person <u>*</u> Bevers Denise			2. Issuer Name and Ticker or Trading Symbol Kindred Biosciences, Inc. [KIN]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)	3. Date of	of Earliest T	ransaction		(Ch	eck all applicabl	e)		
C/O KINDRED BIOSCIENCES, INC., 1555 BAYSHORE HIGHWAY, SUITE 200			(Month/Day/Year) 01/08/2016				Director 10% Owner X Officer (give title Other (specify below) below) Chief Operating Officer				
(4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check					
BURLINGAME	Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Tał	ole I - Non-J	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
	ansaction Date hth/Day/Year)		Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, -	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code v	Amount	(D) Flice					
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.											
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	f 8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

Edgar Filing: Kindred Biosciences, Inc. - Form 4

Security (Instr. 3)			any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (I	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 3.45	01/08/2016		A	59,031	<u>(1)</u>	01/08/2026	Common Stock	59,031	
Reporting Owners										
Reporting Owner Name / Address				Relations	hips					
		Director	10% Own	er Officer		Other				
Bevers Denise C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME, CA 94010		2 200		Chief						
Signa	tures									
	/s/ Dietrick Miller		01/12/2016							
<u>**</u> Signat	ure of Reporting Pe	erson	Date							
Explanation of Responses:										

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option will vest as to 25% after one year following the date of grant, and the remainder will vest in equal monthly installments over the following three years, provided Reporting Person remains in continuous employ of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.